Moreover, thrombocytopenia is a common side effect in myeloproliferative neoplasm patients with JAK1/2 inhibitor therapy, which target in hematopoietic stem and precursor cell mutant JAK2-V617F as well as wile-type JAK2. The gene discussed is JAK2; the disease is myeloproliferative disorder.